AMWatch

Frasalg til kapitalfond giver milliardindtægt til Bagger-Sørensen

Tyggegummikoncernen Bagger-Sørensens salg af nikotintyggegummi-producent indbragte koncernen et milliardbeløb.

Photo: Anders Brohus / Polfoto

Salget af Fertin Pharma til kapitalfonden EQT indbragte Bagger-Sørensen & Co. knap 1,4 mia. kr. Det fremgår af Bagger-Sørensen-koncernens regnskab for 2017, skriver Finans.

Fertin-Pharma er især kendt for sin produktion af nikotinholdigt tyggegummi og har været en del af Bagger-Sørensens tyggegummiimperie, der blandt andet har skabt mærker som Dandy, Stimorol og V6, siden Bagger-Sørensen-familien købte det svenske selskab i 1978.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Savills IM working hard on first Nordic residential investment

The global property investor has plans to expand its growing portfolio in Denmark with a new asset class, residential real estate, "very soon," says Head of Nordics Peter Broström. The manager still believes in the office and retail sectors, despite the pandemic and rising inflation.

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch